Skip to main content
. 2022 Apr 12;13(10):1471–1478. doi: 10.1111/1759-7714.14415

FIGURE 1.

FIGURE 1

Kaplan–Meier curves of progression‐free survival (a) and overall survival (b) from dacomitinib initiation in all patients. Kaplan–Meier curves of sub group progression‐free survival in patients with EGFR exon 21 L858R and those with EGFR exon 19 deletion (c). Kaplan–Meier curves of sub group progression‐free survival in patients with PS 0–1 and those with PS 2 or more (d)